Announcements
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
- Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
More ▼
Key statistics
As of last trade, Corcept Therapeutics Inc (HTD:DUS) traded at 22.17, 23.17% above the 52 week low of 18.00 set on Jan 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.55 |
---|---|
High | 24.61 |
Low | 22.17 |
Bid | 23.24 |
Offer | 23.71 |
Previous close | 22.17 |
Average volume | 65.56 |
---|---|
Shares outstanding | 103.84m |
Free float | 91.99m |
P/E (TTM) | 25.03 |
Market cap | 2.48bn USD |
EPS (TTM) | 0.9542 USD |
Data delayed at least 15 minutes, as of May 02 2024 18:31 BST.
More ▼